This is in line with data from unpublished clinical trials showing that monoclonal antibodies neutralising IL-1β signalling are ineffective in the treatment of patients with stable COPD (http://clinicaltrials.gov/ct2/show/results/NCT00581945). The gene discussed is IL1B; the disease is chronic obstructive pulmonary disease.